Close

Our Blog

< Back to All Articles

Opportunity knocks: drug serialization in Europe and the US

Posted on February 24, 2017 by

Helena Rogers

Sea VisionThe US and European healthcare industry will soon need to adhere to varying pharmaceutical drug serialization legislation.

Despite serialization presenting a challenge for drug manufacturers, it is also gives the industry a unique opportunity to improve patient safety, reduce costly problems associated with counterfeit medicines and preserve its reputation.

Over the next few weeks we’ll be sharing our pharmaceutical serialization blog series written by Zenith Technologies’ serialization director, Carlos Machado and SEA Vision’s senior R&D product manager, Matteo Barbieri.

The series offers an insight into how to comply with the newest regulations on time, on budget and with best practice execution. Next in the series we discuss ‘Safety first, drivers to serialization.’

Read the first full blog here.

Leave a Reply

Got a question? Talk to us We are happy to discuss any queries you may have

Get in touch today